Drug
E2086
E2086: highest development phase Phase 1, developed by Eisai. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Eisai
Trials
| Drug | Phase | Indication |
|---|---|---|
| E2086 NCT07766369 | Phase 1 |
Latest
No recent events.
Follow E2086 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.